Pancreatic Cancer Research

ResearcherShanghai Medical College of Fudan UniversityActive in the last 2 years

Wei Chiang Liu

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0001-5827-7772; OpenAlex author ID A5100431635. Sources: OpenAlex.

Their work

Papers
13 (first author 2, last author 2)
Trials
0
Grants
0
Labs led
1
Collaborators
57
Papers, trials and grants by year

2013: 1 paper · 2014: none · 2015: none · 2016: 1 paper · 2017: 1 paper · 2018: 1 paper · 2019: 1 paper · 2020: 2 papers · 2021: 2 papers · 2022: 3 papers · 2023: none · 2024: none · 2025: 1 paper

Papers 13

  1. Global disparities in the burden of pancreatic cancer (1990-2021): insights from the 2021 Global Burden of Disease study. Co-author DOI 10.1186/s12885-025-14110-2↗
  2. SULF2 enhances GDF15-SMAD axis to facilitate the initiation and progression of pancreatic cancer. Last author DOI 10.1016/j.canlet.2022.215693↗
  3. Increased SPON1 promotes pancreatic ductal adenocarcinoma progression by enhancing IL-6 trans-signalling. Last author DOI 10.1111/cpr.13237↗
  4. Sequestration of Intestinal Acidic Toxins by Cationic Resin Attenuates Pancreatic Cancer Progression through Promoting Autophagic Flux for YAP Degradation. Co-author DOI 10.3390/cancers14061407↗
  5. Improved tumor control with antiangiogenic therapy after treatment with gemcitabine and nab-paclitaxel in pancreatic cancer. Co-author DOI 10.1002/ctm2.398↗
  6. Integrated genomic and transcriptomic analysis reveals unique characteristics of hepatic metastases and pro-metastatic role of complement C1q in pancreatic duc… Co-author DOI 10.1186/s13059-020-02222-w↗
  7. Pancreatic Cancer: A Review of Risk Factors, Diagnosis, and Treatment. First author DOI 10.1177/1533033820962117↗
  8. Molecular markers associated with perineural invasion in pancreatic ductal adenocarcinoma. Co-author DOI 10.3892/ol.2020.11866↗
  9. Prognostic Predicting Role of Contrast-Enhanced Computed Tomography for Locally Advanced Pancreatic Adenocarcinoma. First author DOI 10.1155/2019/1356264↗
  10. Decreased expression of USP9X is associated with poor prognosis in Chinese pancreatic ductal adenocarcinoma patients. Co-author DOI 10.3892/ol.2018.8452↗
  11. High Expression of FAM83B Predicts Poor Prognosis in Patients with Pancreatic Ductal Adenocarcinoma and Correlates with Cell Cycle and Cell Proliferation. Co-author DOI 10.7150/jca.20086↗
  12. Efficacy of Neo-Adjuvant Chemoradiotherapy for Resectable Pancreatic Adenocarcinoma: A PRISMA-Compliant Meta-Analysis and Systematic Review. Co-author DOI 10.1097/md.0000000000003009↗
  13. Influence of perineural invasion on survival and recurrence in patients with resected pancreatic cancer. Co-author DOI 10.7314/apjcp.2013.14.9.5133↗

Closest collaborators

The 25 strongest of 57 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Jian‐Yu Yang · 7 shared papers, 2016–2022 · strength 0.66
  2. Xueliang Fu · 7 shared papers, 2016–2022 · strength 0.66
  3. Yongwei Sun · 7 shared papers, 2016–2022 · strength 0.66
  4. Yan‐Miao Huo · 7 shared papers, 2016–2022 · strength 0.66
  5. Minwei Yang · 6 shared papers, 2016–2022 · strength 0.61
  6. Dejun Liu · 6 shared papers, 2016–2022 · strength 0.59
  7. Junfeng Zhang · 6 shared papers, 2016–2022 · strength 0.54
  8. Rong Hua · 6 shared papers, 2013–2022 · strength 0.53
  9. Gang Wang · 1 shared paper, 2025 · strength 0.30
  10. Genhai Shen · 1 shared paper, 2025 · strength 0.30
  11. Dapeng Xu · 2 shared papers, 2022 · strength 0.25
  12. Zhiyu Zhao · 1 shared paper, 2020 · strength 0.24
  13. Jing Xue · 2 shared papers, 2021–2022 · strength 0.23
  14. Tianci Zhang · 1 shared paper, 2022 · strength 0.16
  15. Jun Li · 1 shared paper, 2022 · strength 0.16
  16. Guangfu Zhao · 1 shared paper, 2022 · strength 0.16
  17. Stephen Jacob Pandol · 1 shared paper, 2022 · strength 0.16
  18. Yuan‐Ping Han · 1 shared paper, 2022 · strength 0.16
  19. Mouad Edderkaoui · 1 shared paper, 2022 · strength 0.16
  20. Li-Peng Hu · 1 shared paper, 2022 · strength 0.13
  21. Jia-Hao Zheng · 1 shared paper, 2022 · strength 0.13
  22. Hong‐Fei Yao · 1 shared paper, 2022 · strength 0.13
  23. Ruizhe He · 1 shared paper, 2022 · strength 0.12
  24. Juanjuan Shi · 1 shared paper, 2022 · strength 0.12
  25. Ping Lu · 1 shared paper, 2022 · strength 0.12

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.